Rise Therapeutics is at the forefront of developing targeted immunotherapy drugs by integrating advanced immunology with insights from microbiome science. The company focuses on creating innovative biologics aimed at treating chronic diseases such as autoimmunity, cancer, and infections. Their approach leverages a proprietary oral delivery platform, known as Tripartite X (TPX), which utilizes synthetic biology methodologies to enhance the efficacy of these therapies. By understanding the complex interactions between the immune system and the microbiome, Rise Therapeutics identifies novel therapeutic targets that can modulate immune responses, thereby promoting human health and well-being.

The company’s pipeline includes several promising candidates, such as R-3750, R-2487, R-5280, and R-5780, each designed to address specific clinical indications. R-3750 targets gastrointestinal inflammatory diseases by enhancing gut barrier integrity, while R-2487 aims to induce regulatory T cell populations to combat autoimmune disorders like rheumatoid arthritis. R-5280 focuses on controlling immune pathways related to type 1 diabetes, and R-5780 is an immune oncology candidate that enhances anti-tumor responses. Rise Therapeutics combines its robust clinical GMP manufacturing capabilities with a strong emphasis on product development to facilitate the rapid translation of laboratory discoveries into effective therapies.

United States

Rise Therapeutics is developing targeted immunological-based biologics using a unique and proprietary oral delivery platform. The company develops unique, first-in-class immune modulatory drugs for the treatment of inflammation, autoimmunity and cancer.

Rise Therapeutics

Company Details